Evidence map›Paper›PMID 26515984›Full record

ReviewAnnual review of medicine2016

Marijuana Legalization: Impact on Physicians and Public Health.

Samuel T Wilkinson, Stephanie Yarnell, Rajiv Radhakrishnan, Samuel A Ball, Deepak Cyril D'Souza

Open access · bronzeAbstract readReview
In one paragraph

Review in Annual review of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 2 pooled it
15.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 2 syntheses or guidelines pooled it, 200 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Structure-based identification of a G protein-biased allosteric modulator of cannabinoid receptor CB1.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Samuel T WilkinsonDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut 06511; email: samuel.wilkinson@yale.edu.
Stephanie YarnellDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut 06511; email: samuel.wilkinson@yale.edu.
Rajiv RadhakrishnanDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut 06511; email: samuel.wilkinson@yale.edu.
Samuel A BallDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut 06511; email: samuel.wilkinson@yale.edu.
Deepak Cyril D'SouzaDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut 06511; email: samuel.wilkinson@yale.edu.
Yale University · US

Funding

Clinical Neuroscience Research Training Program in PsychiatryT32MH019961 · NIMH · YALE UNIVERSITY · PI Christopher John Pittenger · 1996 to 2026
$5.9M
Schizophrenia Research FellowshipR25MH071584 · NIMH · YALE UNIVERSITY · PI Christopher John Pittenger · 2005 to 2026
$4.4M
NEUROBIOLOGY OF CANNABIS EFFECTSR01DA012382 · NIDA · YALE UNIVERSITY · PI D'SOUZA, DEEPAK CYRIL · 2001 to 2009
$1.3M
Imaging Brain Cannabinoid Receptors (CB1) in SchizophreniaR21MH094961 · NIMH · YALE UNIVERSITY · PI D'SOUZA, DEEPAK CYRIL · 2012 to 2013
$383k
Cannabinoids, Neural Synchrony and Information ProcessingR21DA020750 · NIDA · YALE UNIVERSITY · PI D'SOUZA, DEEPAK CYRIL · 2007 to 2008
$354k
Intramural VA VA999999NIDA NIH HHS R01 DA012382NIDA NIH HHS R21 DA020750NIMH NIH HHS 5R25MH071584-08NIMH NIH HHS 5T32MH019961-18NIMH NIH HHS R21 MH094961NIMH NIH HHS R25 MH071584NIMH NIH HHS T32 MH019961
6 · The paper itself

Abstract

Marijuana is becoming legal in an increasing number of states for both medical and recreational use. Considerable controversy exists regarding the public health impact of these changes. The evidence for the legitimate medical use of marijuana or cannabinoids is limited to a few indications, notably HIV/AIDS cachexia, nausea/vomiting related to chemotherapy, neuropathic pain, and spasticity in multiple sclerosis. Although cannabinoids show therapeutic promise in other areas, robust clinical evidence is still lacking. The relationship between legalization and prevalence is still unknown. Although states where marijuana use is legal have higher rates of use than nonlegal states, these higher rates were generally found even prior to legalization. As states continue to proceed with legalization for both medical and recreational use, certain public health issues have become increasingly relevant, including the effects of acute marijuana intoxication on driving abilities, unintentional ingestion of marijuana products by children, the relationship between marijuana and opioid use, and whether there will be an increase in health problems related to marijuana use, such as dependence/addiction, psychosis, and pulmonary disorders. In light of this rapidly shifting legal landscape, more research is urgently needed to better understand the impact of legalization on public health.

Indexed as

CannabisAutomobile DrivingCognition DisordersDronabinolHumansIllicit DrugsMarijuana AbuseMarijuana SmokingMedical MarijuanaOpioid-Related DisordersPrevalencePsychotic DisordersPublic HealthUnited StatesDronabinolIllicit DrugsMedical Marijuanacannabislegalizationmedical marijuanapublic health

Identifiers

PMID26515984
PMCPMC4900958
OpenAlexW2098465493

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.